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Department of Physics, Centre of Physics of University of Minho and Porto, University of Minho, Braga, Portugal
The goal of this study is to provide tools to minimize trial-and-error in the development
of novel lipid-based nanotherapeutics, in favor of a rational design process. For
this purpose, we present case-study examples of biophysical assays that help
addressing issues of lipid-based nanotherapeutics’ profiling and assist in the design
of lipid nanocarriers for therapeutic usage. The assays presented are rooted in
spectroscopic methods (steady-state and time-resolved fluorescence; UV-Vis derivative
spectroscopy; fluorescence anisotropy and fluorescence lifetime image microscopy) and
allow accessing physical-chemical interactions between drugs and lipid nanocarriers,
as well as studying interactions between lipid-based nanotherapeutics and membranes
and/or proteins, as this is a key factor in predicting their therapeutic and off target
effects. Derivative spectroscopy revealed Naproxen’s high distribution (LogD ≈ 3) in
different lipid-based nanocarriers (micelles and unilamellar or multilamellar vesicles)
confirming the adequacy of such systems for encapsulating this anti-inflammatory drug.
Fluorescence quenching studies revealed that the anti-inflammatory drugs Acemetacin
and Indomethacin can reach an inner location at the lipid nanocarrier while being
anchored with its carboxylic moiety at the polar headgroup. The least observed
quenching effect suggested that Tolmetin is probably located at the polar headgroup
region of the lipid nanocarriers and this superficial location may translate in a fast drug
release from the nanocarriers. Fluorescent anisotropy measurements indicated that the
drugs deeply buried within the lipid nanocarrier where the ones that had a greater
fluidizing effect which can also translate in a faster drug release. The drug binding strength
to serum albumin was also compared for a free drug (Clonixin) or for the same drug
after encapsulation in a lipid nanocarrier DSPC:DODAP (2:1). Under both conditions
there is a strong binding to serum albumin, at one binding site, suggesting the need
to produce a stealth nanosystem. Finally the cellular uptake of lipid nanocarriers loaded
with Daunorubicin was investigated in cancer cells using fluorescence lifetime imaging
microscopy. From the images obtained it was possible to conclude that even at short
incubation times (15min) there was a distribution of the drug in the cytoplasm, whereas
for longer incubation periods (4 h) the drug has reached the nucleus.
Keywords: nanotherapeutics’ characterization, derivative spectroscopy, fluorescence quenching, steady-state
anisotropy, HSA binding, fluorescence lifetime imaging microscopy
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INTRODUCTION
In the latest century, Nanotechnology is one of the fastest
increasing technological fields. Recent advances in the
development of new materials with unique properties have
provided exciting new opportunities in different areas, including
environmental applications where nano adsorbents are gaining
importance due to their remarkable capacities to uptake a
wide variety of pollutants (Ali et al., 2015, 2016a,b,c,d,e, 2017).
Simultaneously, Nanomedicine emerges as a continuously
evolving area of research that uses Nanotechnology to produce
nanotherapeutics aiming the progress in the prevention, therapy
and diagnosis of a large spectrum of diseases (Duncan and
Gaspar, 2011; Fornaguera and García-Celma, 2017). Nowadays,
nanotherapeutics have become the promise to overcome many
limitations faced by classical therapy, such as low bioavailability
or poor pharmacokinetics, thus, having a major implication on
public health improvement (Hafner et al., 2014; Fornaguera
and García-Celma, 2017; Gao and Lowry, 2018). For example,
nanotherapeutic’s ability to provide targeted and/or triggered
delivery of drugs, as well as an increase in drug solubility and
decrease in toxicity, describes it as an essential application in
treatment of numerous diseases. Additionally, nanotherapeutics
promote the reduction of certain conventional drawbacks such
as, poor compliance, non-specific delivery, toxicity related to
higher doses, and early body clearance (Hafner et al., 2014).
Nowadays, despite the great optimism concerning
Nanomedicine’s potential impact, nanotherapeutics development
is often made on basis of trial-and-error approaches with poor
in vitro systematic characterization and without considering
the rational design proposed by the pharmaceutical industries
(Duncan and Gaspar, 2011; Hafner et al., 2014; Wacker,
2014). This leads to great investments in nanotherapeutics’
development which fails to fulfill their expected therapeutic
effects at a very late stage of the developmental process. In this
regard, the EU Committee on strategy for nanotechnologies
alerts for insufficient fundamental studies directed to understand
nanotherapeutics’ in vivo fate. Furthermore, Andrew D.
Maynard and his co-authors (in a Nature publication) propose
that the major challenges in nanotechnology for the next 15
years are the development of in vitro methods and models
to predict the nanotherapeutics’ in vivo behavior (Maynard
et al., 2006). Moreover, the European Commission and the
European Technology Platform for Nanomedicine suggests
that a major challenge in nanotherapeutics’ development is the
successful translation of research from academia to production
lines with efficacy, safety, and quality controls to improve the
quality-by-design approach (Duncan and Gaspar, 2011; Hafner
et al., 2014). Failures in research to market translation justify that
only a small number of nanotherapeutics have been approved
and commercialized. A comprehensive analysis of the worldwide
state of investigational and approved nanomedicine products as
of January 2012 has identified a still very short list of marketed
nanotherapeutics (Etheridge et al., 2013). From the 21 marketed
approved nanocarriers for drug delivery 15 are liposomes or lipid
based nanocarriers (AmBisome R©, DaunoXome R©, DepoCyt R©,
DepoDur R©, Doxil R©, Inflexal R© V, Marqibo R©, Mepact R©,
Myocet R©, Visudyne R©, Abelcet R©, Amphotec R©, Fungizone R©,
Diprivan R©, Estrasorb R©) whereas 3 are protein drug conjugates
(Eligard R©, Genexol R©, Opaxio R©) and other 3 are polymer based
nanoformulations (Abraxane R©, Kadcyla R©, Ontak R©) (Weissig
et al., 2014).
From a general standpoint lipid nanocarriers are better
accepted by pharmaceutical companies for therapeutic purposes,
since its lipid components are generally recognized as safe
(GRAS). Furthermore, lipid nanocarriers are biodegradable, and
for that reason considered to not accumulate in the body and
regarded as possibly risk-free (Qi et al., 2017).
Therefore, this study aims to provide a bio-inspired approach
for design and develop lipid-based nanotherapeutics (NT) based
in “in vitro” biophysical techniques. For this purpose, we present
case-study examples of assays that address issues of NT profiling,
as well as, assist in the design of lipid nanocarriers for therapeutic
purposes.
To simplify the practical use of this work, it will be presented
as a toolbox for biophysical-chemical characterization of NT
that can be applied to several lipid formulations (e.g., lipid
vesicles, lipid micelles, cubosomes, solid lipid nanoparticles,
nanostructured lipid carriers, ethosomes, niosomes, etc.) and
therapeutic agents (Figure 1).
The examples presented are divided into two major topics:
(i) pre-formulation studies, focusing on the interactions between
the drug and the nanocarrier, and (ii) performance studies with a
focus on the interactions between NT and biological structures.
In the section of pre-formulation studies, we present strategies
to analyse drug distribution, drug location and drug effect
on NT’s biophysical properties. Drug distribution coefficient
(LogD) between the lipid phases of the NT and the aqueous
phase is studied by derivative spectroscopy, leading to the
determination of drug encapsulation. Drug location in NT
is inferred by fluorescence quenching, where a decrease on
fluorescence intensity of extrinsic probes was measured to
indicate drug distribution and possible orientation within NT.
Furthermore, drug effect on biophysical properties of NT is
studied using fluorescence anisotropy, because for instance a
great increase of the fluidity of the NT lipid system can turn it
into a very leaky and not too stable nanocarrier for the drug. In
the latter section, strategies are presented focusing on analyzing:
NT interaction with plasma proteins by measuring fluorescence
quenching of intrinsic probes, as this is paramount to assure that
the nanocarrier will reach target tissues and will not have an
exceeding circulation time and finally, cellular uptake of drug




The studied drugs (Acemetacin, Indomethacin, Tolmetin,
Naproxen, Clonixin and Daunorubicin), 12-anthroyloxi-stearic
acid (12-AS) probe and Human serum albumin (HSA) were
obtained from Sigma-Aldrich Química, S.L. (Sintra, Portugal).
The other n-anthroyloxi-stearic acid probes designated as
n-AS probes (2-AS, 6-AS and 9-AS) were supplied by
Frontiers in Chemistry | www.frontiersin.org 2 July 2018 | Volume 6 | Article 323
Fernandes et al. Spectroscopic Characterization of Lipid Nanotherapeutics
FIGURE 1 | Schematic representation of the biophysical and chemical toolbox for lipid-based nanotherapeutics’ characterization.
Molecular Probes (Invitrogen Corporation, Carlsbad, California,
USA). All the reagents were used as supplied without
further purification. All other chemicals were purchased
from Sigma-Aldrich Química, S.L. (Sintra, Portugal) with p.a.
or similar quality. Phospholipids: Egg Phosphatidylcholine
(EPC), Hexadecylphosphocholine (HDPC); and 1,2-dioleoyl-
3-dimethylammonium-propane (DODAP were obtained from
Avanti Polar Lipids (INstruchemie, Netherlands). All lipids were
dissolved in Chloroform pro analysis (p.a) from Sigma-Aldrich
Química, S.L. (Sintra, Portugal) to obtain stock solutions of
20mM.
Preparation of Lipid Nanocarriers
Lipid nanocarriers with different structures, compositions and
surfaces charges and sizes were prepared for their wide use as
drug nanocarriers: large unilamellar vesicles of 100 nm (LUVs),
multilamellar vesicles (MLVs), and micelles.
EPC liposomes were prepared in Hepes buffer (pH = 7.4;
I = 0.1M adjusted with NaCl) by the lipid film hydration
method, described in Lasic (1993) and then MLVs were used
without manipulation while LUVs were obtained after successive
extrusions of the MLVs suspension through Nuclepore Track-
Etched polycarbonate membrane filters with different pore
diameters (400, 200, and 100 nm) in a Lipex extruder to obtain
LUVs. The HDPC micellar suspensions were prepared with bi-
deionized water (conductivity <0.1 µS cm−1) and Hepes buffer
(10mM, pH= 7.4; I = 0.1M with NaCl).
In the case of LogD determination studies, for each lipid
nanocarrier system model used (HDPC micelles and MLVs
or LUVs of EPC), two groups of suspensions were prepared.
The first one—the samples—were prepared containing a fixed
concentration of Naproxen and increasing concentrations
of lipid suspension. The second group—the references—
were identically prepared without addition of Naproxen. All
suspensions were subsequently incubated during 30min at
25.0◦C.
To obtain labeled lipid model systems, ethanolic stock
solutions of fluorescent probes were added to the pre-formed
EPC liposomes suspensions in an amount such that the lipid:
probe ratio is always >100:1 (m:m), to prevent structural
changes of the nanocarrier system. The addition of the
probe was done under gentle shaking, followed by 30min
incubation at room temperature and sheltered from light
promoting the total incorporation of the probe into the lipid
bilayer (New, 1990; Lasic, 1993). Increasing concentrations of
NSAIDs (Tolmetin, Indomethacin and Acemetacin) prepared
in Hepes buffer were added to the lipid suspensions labeled
with 2, 6, 9 or 12-AS probes (500µM) to obtain final drug
concentration of 0–600µM. After mild shaking, the suspensions
were protected from light and incubated at room temperature for
2 h.
LUVs of DSPC:DODAP (2:1) loaded with Clonixin or loaded
with Daunorubicin were produced from a direct mixing in
an organic solvent mixture (chloroform: ethanol 8:2) of an
appropriate amount of DSPC, DODAP and drug (Clonixin: 1.52
× 10−3 M or Daunorubicin: 0.5µM) by the lipid film hydration
method followed by extrusion as previously described for EPC
liposomes.
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Derivative Spectroscopy
The absorption spectra of samples and references were plotted
in the 250–500 nm range, on a Perkin-Elmer Lambda 45 UV-
Vis spectrophotometer equipped with a thermostated cell holder
at 25.0 ± 0.1◦C. Derivative spectra were made from absorption
spectra after subtracting the absorption of the references and
using an Excel R© based routine previously published (Magalhães
et al., 2010).
The fluorescence emission spectra of samples and references
were obtained in the 300–500 nm range, at a scanning rate of
50 nm.min−1, during 10 s integration time on a Perkin-Elmer LS-
50B spectrofluorimeter equipped with a thermostated cell holder
at 25.0 ± 0.1◦C and λexcitation =272 nm. Three independent
experiments were carried out. Derivative spectra were made
from fluorescence emission spectra using Microcal Origin 9.0 R©
software further used for data treatment.
Steady-State Spectrofluorimetry Using
Extrinsic Probes
The fluorescence excitation and emission spectra of nanocarriers
labeled with n-AS probes were plotted on Perkin-Elmer LS-
50B spectrofluorimeter using quartz cells of 10mm optical path
themostated at 25.0 ± 0.1◦C. The excitation wavelength was
defined to 381 nm and emission wavelength were set to 452 nm
(2-AS), 446 nm (6 and 9-AS) and 444 nm (12-AS) with excitation
and emission slits between 3 and 6 nm. For correction of the inner
filter effect (Lakowicz, 2014), absorbance spectra of analyzed
suspensions were obtained using a Perkin-Elmer Lambda 45
UV-Vis with 1 cm quartz cell thermostated at 25.0 ± 0.1◦C,
with a scanning speed of 400 nm.min−1. Steady-state anisotropy
determination was performed in Perkin-Elmer LS-50B, with
quartz cell with an optical path of 10mm, thermostated at 25.0
± 0.1◦C and with automatic insertion of vertical and horizontal
polarizers. Temperature value was selected to be well over the
transition temperature of the lipid components to ensure that
the lipid nanocarrier is in the fluid phase and thus warrant the
free rotation of the probe, i.e., r∞≈ 0) (Vincent et al., 1982).
The measurements were performed with an integration time of
50 s, after polarizer placement and with excitation and emission
slits between 3 and 6 nm. The excitation wavelength was defined
to 381 and the emission wavelength was set up considering the
probe: 452 nm (2-AS); 446 nm (6-AS and 9-AS), and 444 nm
(12-AS). Three independent experiments were carried out.
Steady-State Spectrofluorimetry Using
Intrinsic Probes
For HSA-clonixin binding measurements, increasing drug
amounts were added to solutions of HSA at a fixed concentration
(concentration of 6 × 10−4 M equivalent to HSA blood plasma
concentration (Ma andHadzija, 2013) freshly prepared in HEPES
buffer (pH 7.4; I = 0.1M). For binding measurements between
HSA and liposomes loaded with Clonixin, different volumes of
LUVs of DSPC:DODAP (2:1) loaded with 15% of Clonixin were
added to the same fixed concentration of HSA to achieve final
lipid concentrations of 1 × 10−5, 5 × 10−5, 1 × 10−4, 5 × 10−4,
1× 10−3, and 1.5× 10−3 M.
Fluorescence quenching measurements of HSA intrinsic
emission were carried out with a spectrofluorometer, LS-50B
(Perkin Elmer, Waltham, MA) using quartz cells of 10mm
optical path. The excitation wavelength was defined to 280 nm
and emission spectra was recorded between 300 and 450 nm.
The temperature was kept constant and equal to physiological
temperature 37 ± 0.5◦C. The excitation and emission slit widths




For FLIM analysis, Human cervical carcinoma (Hela) cells
were seeded into sterilized 3 cm glass bottom dishes (Mat-
Tek) (100,000 cells/well). After 24 h seeding, the medium was
replaced with fresh medium containing LUVs of DSPC:DODAP
(2:1) loaded with Daunorubicin (0.5µM equivalent drug
concentration), and cells were incubated at 37◦C for 15min
and 4 h. The fluorescence lifetime distribution was measured
by a homemade FLIM setup (Bernardo et al., 2014) based in
a femtosecond laser Ti:sapphire with a natural frequency of
800 nm and 100 fs pulse duration as a radiation source. The decay
profiles were recorded using the double of the laser frequency
as an excitation source (λexc = 400 nm) and the emission was
collected at λemi = 592 nm corresponding to the maximum of
the fluorescent band of the drug (Than Htun, 2009).
RESULTS
Pre-formulation Studies
Distribution Coefficient Studies to Evaluate
Interaction Between Drug and Lipid Nanocarriers
To understand the numerous mechanisms related to a drug
loaded in a lipid colloidal based nanocarrier, it is important to
study the interactions between the drug and the lipid components
of the nanocarrier or between the drug and a mimetic model
system of the nanocarrier used for drug encapsulation. One of
the most important parameters to evaluate these interactions is
the drug distribution between lipid/aqueous phases, which allows
evaluating if the drug is more distributed in the hydrophobic or
hydrophilic microenvironment of the nanocarrier. Considering
the type of nanocarrier designed there are several models that
may be used to determine drug distribution coefficient (LogD):
micelles and lipid vesicles (LUVs and MLVs). The LogD of
Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), in
different biphasic lipid/aqueous systems will be presented as an
example of this pre-formulation study.
In Figure 2, it is possible to observe that the scattering
due to the lipid vesicles is different according to the model
system used. MLVs (Figure 2C) cause scattering of incident light,
so the application of derivative spectroscopy is required. The
first derivative of the spectra partly eliminates the interference
caused by the scattering of light, while the second derivative
eliminates completely the light scattering interferences, allowing
a better distinction of characteristic spectral details of a drug/lipid
interaction. LUVs suspensions (Figure 2B), although more
translucent than MLVs suspensions can also cause incident light
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scattering in absorption spectra. Derivative spectroscopy allows
partial elimination of this type of interference but not its total
suppression, as can be seen in Figure 2. This is due to a marked
Rayleigh dispersion which leads to a noticeable increase in light
dispersion as it progresses to smaller wavelengths (Braun, 1987;
Gorog, 2018). The spectral interference caused byHDPCmicelles
(Figure 2A) is very small, thus, the LogD calculation can be
performed either directly from the absorption spectra or from
the derivative spectra that leads to the complete elimination of
the light scattering interference. The mathematical treatment of
all spectra was performed using a previously developed routine,
Kp calculator (Magalhães et al., 2010).
Considering the facts presented before, LogDmicelle/aqueous of
Naproxen was estimated directly from the λmax of absorption
spectra (Figure 3A). In the figure, an example of the non-linear
regression is represented (Abs vs. [L]) obtained by adjusting
Equation 1 to the experimental data: absorbance (Abs) at
λmax = 272 nm obtained for increasing concentrations of HDPC
micelles ([L]).
In the fitting expression, T, a and l subscripts stand
respectively for total, aqueous and lipid and D is the distribution
coefficient from which LogD is calculated.







The same fitting was applied to the other absorption λmáx (262
and 330 nm) and LogD-values are represented in Table 1.
The LogD determination by derivative spectrophotometry is
based on a similar equation where instead of values taken at the
λmax of the absorbance spectra, values are taken at the peaks
of the correspondent n order derivative spectra where the light
scattering interference of the nanocarrier has been eliminated

















In the aforementioned equations, the lipid concentration [L]
expressed in molL−1 is multiplied by the calculated volume of the
lipid nanocarrier in Lmol−1 (Vl) to obtain a dimensionless value
of LogD that can be compared with others LogD values described
in the literature for other systems (Lúcio et al., 2006).
Although, in the case of drugs distributed in the
micelle/aqueous phase system, it is possible to calculate LogD
from the absorption spectra, the derivative spectroscopy can
also be applied to increase the resolution of poorly differentiated
bands (Kitamura and Imayoshi, 1992; Kitamura et al., 1995;
Omran et al., 2001). Theoretically, LogD values can be calculated
from dnAbsT/dλ
n at any wavelength. However, to increase
signal/noise ratio, the dnAbsT/dλ
n values for heterogeneous
samples should be obtained for λmax or λmin values of the
derivative spectra (peaks of the derivatives). LogD values
obtained for different peaks of the derivatives (1st derivative,
λ = 242 nm and 2nd derivative, λ = 248 nm)—represented in
Table 1—were shown to be concordant confirming the total
elimination of the light scattering caused by micelles.
Figure 3 also represents the first (Figure 3B) and second
(Figure 3C) derivative spectra where it is possible to observe
a shift of λmax characteristic of a drug distribution into
environments of lower polarity (distribution of Naproxen into
the lipid phase) (Kitamura et al., 1995), with a decrease in
the intensity of the bands as the lipid concentration increases.
Isosbestic points are also observed indicating the existence of a
balance between two drug forms (in interaction with the lipid
medium and free in aqueous medium) and the eradication of the
light scattering interference (Saakov et al., 2015).
From Table 1 it is worth noting that results obtained from
the UV/Vis spectra and derivative spectra give very similar
values of LogD, confirming that the insignificant light scattering
interference of micelles is easily eliminated by derivation of the
absorption spectra. Thus, the average LogD value obtained for
Naproxen distribution in the micelle/aqueous phase is 3.08 ±
0.07.
Figure 4A represents the Naproxen absorption spectra when
encapsulated in MLVs nanocarriers. The baseline of the
absorption spectra increases greatly with increasing MLVs
concentration, indicating a light scattering effect. Hence, for a
proper quantification of Naproxen LogD the first and second
derivatives of the spectra were required. In Figure 4B, it is
possible to observe that the interference of the light scattering
effect is minimal forλ > 235 nm values. Indeed, from these values
of λ, the references of 1st derivative absorption spectra (dashed
light gray lines) have a signal close to zero, making possible the
calculation of Naproxen LogD at λ = 244 nm. The same trend
can be observed in the second derivative spectra (Figure 4C);
however, the light scattering is minimal for λ > 240 nm, being
possible to determine Naproxen LogD at λ= 250 nm. The fittings
of Equation 2 to the experimental data, through a non-linear
regression, that were used to obtain the D and LogD values
presented in Table 1, are also represented in the same figure.
The LogD value of a drug can also be determined by
spectrofluorimetry, if the drug is a fluorescent compound, and if
there is a variation in a fluorescence parameter (e.g., fluorescence
emission intensity, λmax of the emission) due to its distribution in
lipid/aqueous phases (Santos and Castanho, 1996; Pereira-Leite
et al., 2013). The fluorescence emission intensity, I, can be used
to calculate the distribution D, and the correspondent LogD of a
fluorescent drug between the lipid and aqueous phases, through
Equation 3:




This equation is similar to that presented for the determination
of D by spectrophotometry (Equation 1). However, instead of
absorbance, it is measured the fluorescence emission intensity
(IT) of the drug distributed in lipid nanocarriers accounting
for the fluorescence emission intensity contributions of drug
distributed in the lipid (Il) and aqueous (Ia) phases which can be
related to D and then LogD values (Santos and Castanho, 1996;
Santos et al., 1998).
The determination of drug LogD in lipid/aqueous
phase by fluorescence methods is more advantageous
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FIGURE 2 | (A) Representative scheme of a micelle, its absorption spectra and second derivative spectra obtained for increasing HDPC concentrations (100–900µM)
in Hepes buffer pH = 7.4 and I = 0.1M. (B) Representative scheme of LUVs, its absorption spectra and second and third derivative spectra obtained for increasing
concentrations liposomes (100–1,000µM) in Hepes buffer pH = 7.4 and I = 0.1M. (C) Representative scheme of MLVs, its absorption spectra and first and second
derivative spectra obtained for increasing concentrations of liposomes (40–350µM) in Hepes buffer pH = 7.4 and I = 0.1M.
Frontiers in Chemistry | www.frontiersin.org 6 July 2018 | Volume 6 | Article 323
Fernandes et al. Spectroscopic Characterization of Lipid Nanotherapeutics
FIGURE 3 | Schematic representation of mathematical treatment (fittings according Equations 1, 2) applied to Naproxen experimental absorption spectra with
increasing concentrations of HDPC micelles (0–900µM) in Hepes buffer pH = 7.4 and I = 0.1 M. (A) Naproxen absorption spectra including as an inset the plot of
drug absorbance values at λmax = 272 as a function of lipid concentration and the respective fitting by non-linear regression method. (B) First derivative of the
Naproxen absorption spectra and the correspondent fitting at λmax = 242 nm. (C) Second derivative of the Naproxen absorption spectra and the correspondent
fitting at λmax = 248 nm.
over UV-Vis spectrophotometric methods, since the
light scattering caused by the lipid media is reduced
(Figure 5A) and can be totally eliminated with the 1st
and 2nd derivative of the fluorescence emission spectra
(Figures 5B,C).
The LogD determination by derivative spectrofluorimetry is
based on a similar equation where instead of values taken at the
λmax of the fluorescence emission spectra, the values are taken at
the peaks of first derivative spectra where the nanocarrier light
scattering interference has been eliminated (Ferreira et al., 2003,

















Naproxen is a fluorescent drug with λmax of excitation at 262,
272 and 330 nm. The LogD of Naproxen in a LUVs/aqueous
media cannot be determined by derivative spectrophotometry
since λmax of the derivative spectra (244 and 250 nm) correspond
to values of λ where spectral interference of LUVs is very
Frontiers in Chemistry | www.frontiersin.org 7 July 2018 | Volume 6 | Article 323
Fernandes et al. Spectroscopic Characterization of Lipid Nanotherapeutics
TABLE 1 | Values of lipid/aqueous distribution coefficient (D and LogD) of Naproxen obtained from the absorbance spectra and from the derivative of the absorbance
spectra.
LogD of Naproxen in a lipid/aqueous system determined by spectrophotometry and derivative spectrophotometry
D-values calculated from the absorbance spectra
(Equation 1)
D-values calculated from the derivative spectra
(Equation 2)
Average Log Da
1st Derivative 2nd Derivative
HDPC Micelles
λ = 262 nm λ = 272 nm λ = 330 nm λ = 242 nm λ = 248 nm
1,091 ± 389 1,131 ± 304 1,233 ± 78 1,279 ± 79 1,266 ± 73 3.08 ± 0.07
EPC MLVs
λ = 244 nm λ = 250 nm
ND 1,644 ± 77 1,441 ± 40 3.30 ± 0.03***;ns
LogD of Naproxen in a lipid/aqueous system determined by derivative spectrofluorimetry
D values calculated from the
fluorescence emission spectra
(Equation 3)





λ = 359 nm λ = 344 nm λ = 376 nm
3,244 ± 150 1,809 ± 194 1,812 ± 190 3.25 ± 0.04ns
EPC LUVs
λ = 359 nm λ = 344 nm λ = 376 nm
3,950 ± 450 2,237 ± 524 2,544 ± 421 3.38 ± 0.09****;ns
aThe value corresponds to the mean and respective standard deviation obtained for all wavelengths of at least three independent assays. Comparisons were performed using a Krauskal-
Wallis test followed by Dunn’s Post-hoc test, for the following paired LogD values obtained for MLVs and LUVs vs. LogD values obtained for micelles; LogD values obtained for MLVs
vs. LogD values obtained for LUVs. ****P < 0.0001, ***P < 0.001; ns, not significant; ND, not determined.
high (Figure 2B). Therefore, the LogD of Naproxen in a
LUVs/aqueous media was determined by spectrofluorimetry and
derivative spectrofluorimetry. For comparison with the results
obtained by derivative spectrophotometry, the LogD of Naproxen
in a MLVs/aqueous media was also determined by derivative
spectrofluorimetry (Table 1).
The fluorescence emission spectra obtained for lipid
nanocarriers containing Naproxen (Figure 6A left) shows a
maximum fluorescence intensity at λ = 359 nm. Because of
the light scattering caused by the lipid phase, the emission
spectrum of Naproxen in the presence of MLVs requires the
application of the derivative method, applying Equation 4 to the
emission spectra. The first derivative spectra obtained are shown
in Figure 6A (right). In this latest figure a well-defined isosbestic
point can be observed indicating elimination of the effects related
to residual light scattering. By derivative spectrofluorimetry, the
calculation of D and then LogD of Naproxen was performed by
fitting Equation 4 to the values of 1st order derivative peaks (at
λ= 344 nm and λ= 376 nm) as a function of lipid concentration
(d1IT/dλ
1 vs. [L]) through a non-linear regression (Figure 6B
left and right). Although the spectral interference caused by the
emission of the lipid phase is small until high concentrations of
lipid are reached, its complete elimination occurs by application
of the 1st derivative, validating the derivative method for LogD
determination by spectrofluorimetry.
The average LogD value obtained for Naproxen distribution in
theMLVs/aqueous phase is 3.25± 0.04 and, in the LUVs/aqueous
phase is 3.38± 0.09.
Studies to Predict Drug Location in Lipid Nanocarrier
After quantifying the drug distribution between the lipid and
aqueous phases of the nanocarrier system, it is important to assess
where the drug will be most likely located within the lipid phase
of the nanocarrier.
For this purpose, it is possible to label the lipid nanocarrier
system with fluorescent extrinsic fluorophores, such as n-AS
probes. n-AS probes are made of stearic acid with an anthracene
fluorescent group located at different points of the acyl chain
(e.g., 2, 6, 9, and 12). When incorporated in a lipid nanocarrier,
their position will be well-defined and they will work asmolecular
rulers capable of labeling different depths (Lakowicz, 2014).
In this regard, labeled nanocarriers (MLVs of EPC) were used
to incorporate three NSAIDs: Tolmetin, Indomethacin and
Acemetacin as an example of the application of these studies.
For all three NSAIDs tested a decrease in the intensities of
fluorescence emitted by the fluorophores incorporated in MLVs
can be observed. Additionally, the fluorescence quenching effect
observed is concentration dependent.
In the case of Tolmetin and Acemetacin, the fluorescence
decreases without meaningful changes in the excitation and
emission spectra and only a decrease in band intensity is observed
(data not shown), suggesting a fluorescence quenching occurring
by collisional processes between drugs and fluorophores
(Lakowicz, 2014). This type of fluorescence quenching can be
described by the Stern-Volmer linear plots (Equation 5 and
Figures 7A,B) where the fluorescence emission intensities of
the labeled nanocarrier in the absence (I0) and in the presence
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FIGURE 4 | (A) Naproxen absorption spectra with increasing concentrations of MLVs of EPC (0–622µM) in Hepes buffer pH = 7.4 and I = 0.1M (B) First derivative
spectra (left) and correspondent nonlinear fitting (right) of derivative absorbance values at λmax = 244 nm as a function of lipid concentration [L]. (C) Second derivative
spectra (left) and correspondent nonlinear fitting (right) of derivative absorbance values at λmax = 250 nm as a function of lipid concentration [L].
(I) of the quencher (drugs) are plotted against the quencher
concentration [Q] and it is possible to obtain linear relations






− 1 = K
app
SV [Q] (5)
The efficacy of the quencher (NSAID) to deactivate the














q is independent of intrinsic microenvironment changes
sensed by each probe, that are reflected in the different values
of τ0, i.e., lifetime of the excited state characteristic of each
probe (Chalpin and Kleinfeld, 1983). However, this parameter is
dependent on several other factors: variations in the collisional
frequency between probe and quencher; fluorescence quenching
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FIGURE 5 | (A) Fluorescence emission spectra and its first derivative spectra (B) and second derivative spectra (C) for increasing concentrations of MLVs of EPC
(25–300µM) in Hepes buffer, pH = 7.4 and I = 0.1M.
efficiency of each probe/quencher pair; radius of probe and
quencher and diffusion coefficient, which varies inversely with
viscosity of the medium. Considering that the fluorophore and
quencher radius, as well as, the intrinsic properties of the
fluorophore (τ0 and diffusion coefficient) are constant values for
all probes, then K
app
q variations reflect changes in the collisional
frequency between fluorophore and quencher. These variations,
which are dependent on the relative proximity between probe
and quencher may be used to infer the relative location of a drug
(quencher) in the lipid nanocarrier (Sikaris and Sawyer, 1982;
Chalpin and Kleinfeld, 1983).
Table 2 presents the constants K
app
q obtained for the three
NSAIDs studied and for the four labeled lipid nanocarriers.
Regarding Acemetacin, the relative efficiency of fluorescence
quenching for the different n-AS probes followed the order: 2-
AS≈6-AS<9-AS<12-AS, indicating that Acemetacin can reach
an inner location at the lipid nanocarrier. Tolmetin K
app
q values
are significantly lower than those obtained for Indomethacin
and Acemetacin which indicates that Tolmetin interacts with all
probes, but to a lesser extent. Furthermore, K
app
q values suggest
a preferential location of Tolmetin at the polar headgroup region
of the lipid nanocarriers, since the relative efficiency of quenching
followed the order: 2-AS > 6-AS≈9-AS≈12-AS.
The Stern-Volmer plots of the fluorescence quenching
provoked by increasing concentrations of Indomethacin are
not linear and present positive deviations (Figure 7C). Positive
deviations from the Stern-Volmer equation are often observed
when the extent of quenching is large and these deviations
from linearity indicate that the quenching mechanism cannot be
explained solely by a collisional mechanism (Lakowicz, 2014).
There is an apparent static quenching component caused by
the close proximity of deactivating drug and fluorophore at
excitation moment. The quenching is still collisional, but the
existence of fluorophores and quenchers located very close
to each other causes an immediate fluorescence deactivation
and therefore the fluorophore and the drug appear to form
non-fluorescent complexes (Lakowicz, 2014). This type of
fluorescence quenching is usually interpreted in terms of a
“sphere of action” (Equation 7) within which the possibility of







Where I0 and I are, respectively, the corrected fluorescence
intensity of the fluorophores in the absence and presence of the
drug (quencher), [Q] is the drug concentration, K
app
SV corresponds
to Stern-Volmer constant relative to fluorescence quenching and
Vapp is the apparent volume of the sphere of action.
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FIGURE 6 | (A) Fluorescence emission spectra (left) of MLVs of EPC (25–300µM) containing a fixed Naproxen concentration (0.4µM) in Hepes buffer pH = 7.4 and
I = 0.1M and respective first derivative of Naproxen fluorescence emission spectra (right). (B) Correspondent nonlinear fitting (Equation 4) of derivative fluorescence
emission values at λmax = 344 nm (left) and at λmin = 376 nm (right) as a function of lipid concentration.
By representing graphically I0
(Ie[Q]Vapp
) as a function of [Q],
linear relations were obtained in which the slope corresponds
to K
app
SV (Figure 7D). Thus, Indomethacin quenching efficiency
followed approximately the same order as that obtained for
Acemetacin: 2-AS <6-AS <9-AS <12-AS. Increasing values of
K
app
q follows the depth of the fluorophore suggesting that, like
Acemetacin, Indomethacin is also able to reach a more inner
location within the lipid nanocarrier.
Studies to Predict How Drug Encapsulation Affects
the Biophysical Properties of Lipid Nanocarrier
To understand the extent to which the lipid nanocarrier
system can be affected by the drug loaded, it is important to
analyse certain biophysical properties of the nanocarrier system
and how they were impacted by the presence of the drug.
Indeed, the evaluation and prediction of possible changes in
the nanosystem’s microviscosity is an important parameter to
consider when choosing a lipid nanocarrier. For example, if
including the drug in the lipid nanocarrier alters considerably
the microviscosity of the system, it can result in the system
becoming too fluid to carry the drug during the required
time after administration, and the lipid composition should
perhaps be revised to convey more rigid domains. Microviscosity
changes induced by the NSAID drugs Tolmetin, Indomethacin
and Acemetacin were evaluated by measuring the steady-state
fluorescence anisotropy of n-AS probes incorporated in MLVs
made of EPC.
Small changes in the stiffness of the environment surrounding
the probe cause changes in the probe’s rotational motion
(Lakowicz, 2014). Thus, any correlation time variation, θ will






Where the temperature (T) is in Kelvin (K), R represents the gas
constant and V is the rotational unit volume.
The rotational correlation time (θ) of a probe inserted in
a lipid nanocarrier can be calculated from the steady-state
fluorescence anisotropy rss measured values using the following
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FIGURE 7 | Variations of relative fluorescence intensity (I/I0) at 25.0
◦C of 2-AS (H), 6-AS ( ) 9-AS ( ) and 12-AS () probes incorporated in MLVs (500µM) as
function of increasing concentrations of Tolmetin (A) Acemetacin (B) and Indomethacin (C) in Hepes buffer pH = 7.4 and I = 0.1M. Stern-Volmer linear regressions
were also aplied to evaluate the quenching efficiency promoted by Tolmetin (A), Acemetacin (B), and Indomethacin (D).
TABLE 2 | Fluorescence apparent bimolecular constants, K
app
q determined by fluorescence quenching of n-AS probes (incorporated in MLVs at 25.0
◦C) by each NSAID
studied.










Tolmetin 0.768 ± 0.001 0.638 ± 0.001 0.545 ± 0.001 0.612 ± 0.001
Acemetacin 5.194 ± 0.006**** 4.424 ± 0.002**** 4.804 ± 0.005**** 5.675 ± 0.005****
Indomethacin 4.013 ± 0.006** 4.029 ± 0.001** 4.086 ± 0.005** 4.181 ± 0.002*
§(x10−11 ) M−1s−1
§values correspond to the mean and respective standard deviation obtained for all wavelengths of at least three independent assays. Comparisons were performed using a Krauskal-
Wallis test followed by Dunn’s Post-hoc test, for the following paired observations: K
app
q values obtained for tolmetin vs. K
app
q values obtained for acemetacin and indomethacin. ****P <
0.0001, **P < 0.01, *P < 0.05.







Where r0 and τ are respectively the fundamental anisotropy
of the probe and its lifetime values during the excited state
(Vincent et al., 1982), considering that the rotational motion
of the probe was not hindered (r∞ ≈ 0) a condition that
is assured when measurements are made above the main
phase transition temperature. Since θ gives indications about
probe motion, it indirectly reports the fluidity of the lipid
environment surrounding the probe and how is it affected by the
presence of increasing concentrations of the drug inserted in the
lipid nanocarrier. For the three NSAIDs tested (Indomethacin,
Acemethacin and Tolmetin) θ values decreased with the addition
of increasing drug concentrations indicating a fluidizing effect
observable for all the tested drugs (Figure 8).
To establish comparisons between the NSAIDs studied in
terms of fluidity efficacy, the respective FE25 values were
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calculated as the concentration in lipid phase ([Q] in M) of
each compound required to increase the fluidity of the lipid
nanocarrier in 25% (Table 3).
Performance Studies
Binding to Serum Albumin to Evaluate Distribution to
the Target Tissues
After entering the body and being absorbed, drugs reach the
systemic circulation where they can strongly bind to plasma
proteins. These interactions, can alter their overall characteristics
ultimately changing their bioavailability, biodistribution, efficacy,
and excretion. In this way, drug-protein interactions and,
above all, interactions between drugs and human serum
albumin (HSA) should not be overlooked (Trynda-Lemiesz,
2004; Liu et al., 2012). HSA is the most abundant protein
in plasma, serving as a storage and transport protein for
several endogenous and exogenous compounds. This soluble
monomeric protein is produced by the liver and is responsible
not only for the transport of lipophilic drugs but also
hormones and fatty acids. In addition, HSA promotes osmotic
pressure regulation and due to the numerous binding sites
identified can reversibly bind to numerous drugs (Liu et al.,
2012).
The drug-HSA complex works as a temporary storage, capable
of preventing compound elimination and thus, preserves the
drug’s effective concentration in plasma. This interaction also
regulates the free and active blood concentration of the drugs
providing a prolonged effect (Carlo and Enrico, 2002). On the
other hand, since mostly unbound compounds can permeate
cellular membranes, drugs binding to plasma proteins precludes
the permeation of those barriers. Therefore, if the drug, which
is being used in a therapeutic formulation is extremely bound
to plasma proteins and the reversal binding kinetics are slow,
only a small amount of drug will be available to permeate
membranes and induce the desired physiological effect (Kerns
and Di, 2008).
Succinctly, due to HSA high concentration in plasma and
drugs binding affinity to HSA, drug-HSA interactions are an
important factor to be considered on the development of new
drugs and have been broadly studied by various methods (Yang
et al., 2014). Bearing this in mind, the affinity to HSA of the
NSAID Clonixin and of a formulation DSPC:DODAP(2:1) LUVs
loaded with Clonixin was assessed by fluorescence quenching
of protein residues, highlighting the intrinsic fluorescence
contribution of tryptophan, located in the hydrophobic cavity
and, in a smaller amount, tyrosine.
Both performed studies of HSAwith the addition of increasing
concentrations of Clonixin and HSAwith the addition increasing
concentrations of DSPC:DODAP(2:1) loaded with Clonixin, have
shown a decrease in the intensity of HSA intrinsic fluorescence,
indicating a binding between HSA and ligands under study (data
not shown). Following a set of specific conditions, a balance
between protein free form and bound form can be established.
This balance is commonly quantified in terms of the dissociation
constant (Kd) for the binary complex at equilibrium and can be
determined by fluorescence quenching according to Equation 10





In this way, Kd can be determined according to a Langmuir
isotherm that establishes a relation between the concentration of
the complex ([HSA-ligand]) and the concentrations of free ligand









The fluorescence quenching of tryptophan and tyrosine residues
is equivalent to the concentration of the complex ([HSA-
ligand]). Thus, by measuring the fluorescence emission of HSA
at the wavelength of maximum intensity (λmax = 344 nm)
in the absence of ligands, and considering this value as 100%
fluorescence intensity, it is possible to calculate a fluorescence
quenching percentage obtained by adding increasing ligand
concentrations. Plotting the fluorescence quenching values as
function of ligand concentration and applying a non-linear
fit according to Equation 12, Kd-values can be determined
(Copeland, 2000; Azevedo et al., 2013):





Where, ymax is the maximum value of fluorescence quenching
reached and n are the number of binding sites.
As an example, in Figure 9, it is presented HSA fluorescence
quenching (%) due to the complex formation of HSA-Clonixin
as function of NSAID concentration (4.3× 10−6, 8.7× 10−6, 2.2
× 10−5, 4.3 × 10−5, 6.5 × 10−5, 8.7 × 10−5, and 1.1 × 10−4 M)
where a non-linear fit of the experimental data was achieved by
application of Equation 12.
As can be observed in Figure 9 there is an increase
in fluorescence quenching with the increase of Clonixin
concentration, proving drug binding to HSA. By applying a non-
linear fitting according to Equation 12, it was possible to calculate
not only the Kd = 9× 10
−5 ± 8.4× 10−6 M but also the number
of specific binding sites of HSA (n = 1 ± 0.008) involved in the
binding of this plasma protein to Clonixin.
The relative affinity or binding strength of protein-ligand
complexes (Kb) is inversely proportional to the value of Kd
meaning that a lower Kd value implies a greater binding strength.
Thus, the binding constant and the number of binding location
sites results obtained for both interactions, HSA-Clonixin and
HSA-DSPC:DODAP(2:1) loaded with 15% of Clonixin, are
presented in Table 4.
According to the results presented in Table 4 it is possible
to conclude that both studied ligands strongly bind to HSA in
only one binding site. However, there is a significant difference
between the strengths of these bindings (P < 0.0001).
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FIGURE 8 | Fluidizing effect (%) caused by increasing concentrations of quenchers [Q]: Tolmetin (), Acemethacin and ( ) and Indomethacin ( ), in MLVs of EPC
(500µM, in Hepes buffer pH = 7.4 and I = 0.1M) labeled with n-AS probes: (A) 2-AS; (B) 6-AS; (C) 9-AS and (D) 12-AS.
TABLE 3 | Values of NSAID concentrations (M) required to obtain 25% of fluidizing effect (FE25) in the lipid nanocarriers MLVs of EPC (500µM, pH 7.4) labeled with n-AS
probes.
Drug 2-AS 6-AS 9-AS 12-AS
Tolmetin 0.4112 ± 0.0001122 0.3955 ± 0.0001582 0.3633 ± 0.0001453 0.2272 ± 0.00009089
Acemetacin 0.1492 ± 0.0005921**** 0.1346 ± 0.0005386* 0.0879 ± 0.0003514**** 0.0459 ± 0.0001838****
Indomethacin 0.1684 ± 0.0005567* 0.1255 ± 0.0005021**** 0.0953 ± 0.0003812* 0.0532 ± 0.0002129*
The values of FE25 correspond to the mean and respective standard deviation obtained for at least three independent assays. Comparisons were performed using a Krauskal-Wallis
test followed by Dunn’s Post-hoc test for the following paired observations: FE25 values of Tolmetin vs. FE25 values of Acemetacin and Indomethacin. ****P<0.0001, *P < 0.05.
Studies of Nanocarriers Uptake and Intracellular Drug
Distribution
To further monitor Daunorubicin’s intracellular release
dynamics of LUVs of DSPC:DODAP (2:1) a FLIM technique
was employed, which is able to distinguish between the “free
state” and “DNA-bound state” of the drug by measuring its
fluorescence lifetime with high spatial resolution inside of the
cell.
In the FLIM system used the fluorescence photon emission
decay is stored in histograms. The decay time of each pixel in
the FLIM image is generated from the recorded histogram. With
this method, we observe the release dynamics of the nanocarrier
drug content inside the cell at exact location, evaluating the
distribution of the mean lifetime of the drug by a multi-
exponential fit of the experimental data.
Daunorubicin, as other anthracycline drugs, presents a mean
lifetime larger upon DNA binding in contrast with its free state
(Dai et al., 2008; Than Htun, 2009; Chen et al., 2012; Basuki
et al., 2013). However, besides the DNA intercalation there is
also a propensity of anthracycline drugs of being oxidized to
semiquinone, an unstable metabolite, which quickly reacts with
oxygen to produce reactive oxygen species (Zhu et al., 2016). This
results in drug’s decay time decrease, due to quenching by the
oxygen radical formed.
The time-resolved fluorescence decay curves of the
Daunorubicin in the intracellular environment was evaluated
by a multi-exponential model. This multi-exponential analysis
was necessary because the lifetime of a fluorescent molecule
strongly depends on its surrounding. Moreover, cells are a
dynamic and complex system with a slight auto fluorescence. For
that reason a large distribution of the decay times is expected,
instead of single decay. A bi-exponential model was used and
allowed to distinguish two components. One of the components
is associated with the drug, whereas the second component has
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FIGURE 9 | HSA fluorescence quenching (%) as a function of increasing
Clonixin concentrations (4.3 × 10−6, 8.7 × 10−6, 2.2 × 10−5, 4.3 × 10−5,
6.5 × 10−5, 8.7 × 10−5, and 1.1 × 10−4 M). A non-linear fit according to
Equation 12 is presented. Experimental data is presented as average value ±
standard deviation of 3 independent assays).
TABLE 4 | Binding constant (Kb) and number of binding locations (n) of Clonixin





Clonixin 111 ± 10 1 ± 0.008 0.999
DSPC:DODAP (2:1) + 15% Clonixin 143 ± 39**** 1 ± 0.052ns 0.938
§(x10−2 ) M−1.
The values of Kb and n correspond to the mean and respective standard deviation
obtained for at least three independent assays. Comparisons were performed using non-
parametric Mann-Whitney test, comparing cumulative distributions between Formulation
+ 15% drug vs. drug. ****P < 0.0001; ns, not significant.
a slow decay time, around 3 ns with a very low amplitude. This
component is associated to the cell auto fluorescence.
Anthracyclines toxicity mechanism depends on DNA
intercalation, to inhibit its transcription. In this regard Figure 10
provides a solid evidence that confirms the successful entrance
of the drug at the specific target, nucleus. Figure 10A represents
the intracellular distribution profile of the drug after cells being
incubated during 15min with the lipid nanocarrier containing
Daunorubicin. It is observed that the major drug content is
still in the cytoplasm as some nucleus are still uncolored. In the
respective histogram the fast component dominates. However,
in the colored picture it is already visible that a small fraction of
the drug has already reached the nucleus. Figure 10B represents
the drug distribution profile after 4 h of cellular incubation
with loaded lipid nanocarriers. In the respective histogram a
second band, corresponding to a slow decay, appears and it is
accompanied by the increase of the fluorescence intensity in the
nucleus. This indicates a drastic increase of the anthracycline
drug concentration inside the nucleus and suggests drug
intercalation within the DNA. In colored picture presented
in Figure 10B it is possible to observe longer lifetime values
correspondent to drug-DNA complexes (blue colored nucleus),
as well as shorter decay time of 1.5 ns (green colored nucleus)
probably due to quenching by the oxygen radical formed and
cytoplasm (red colored) where drug is not bound to DNA, thus
presenting the shortest decay time.
DISCUSSION
Comparing lipid aggregates with different organizational
complexities, HDPC micelles have the advantage of being
more homogeneous, causing less spectral interference, namely
lack of light scattering and simpler and faster preparation
thus, being an efficient way to predict results of studies with
liposomes (Cuccovia et al., 1999). However, in this study, LogD
values of Naproxen in micelles of HDPC were significantly
smaller than LogD values of Naproxen in liposomes (Table 1).
This might be related with the described high lipophilicity of
this NSAID that possesses LogP in octanol/aqueous system
of 3.96 (Yoo et al., 2003). Indeed, liposomes provide higher
distribution opportunities for lipophilic drugs because, in
comparison with micelles, liposomes possess lipid bilayers
(Bozzuto and Molinari, 2015). On the other hand, concerning
the use as lipid nanocarriers, liposomes are considered to be
the most popular drug-carrier system known to date (Bozzuto
and Molinari, 2015). LUVs, presenting a single bilayer and
a fairly large volume of aqueous solution in the interior, are
preferable for more hydrophilic drugs, whereas MLVs with
a higher entrapment volume and greater number of lipid
bilayers are preferred for more lipophilic ones (Pinheiro
et al., 2011). Also the release kinetics is considered different
for these types of vesicles, and LUVs are known for having
faster drug release rates (Bozzuto and Molinari, 2015). Despite
Naproxen’s high lipophilicity the drug presented no significant
difference regarding its distribution in MLVs or LUVs. In fact
the equal affinity of Naproxen for either liposomal structures
may be related to the presence of methyl groups and a
naphthalene based planar molecular structure allowing an
efficient interpenetration within the vesicle lipids by adopting
a molecular conformation more adaptable to the phospholipid
chains.
Fluorescence spectroscopy has proved to be a more suitable
method than derivative UV-Vis spectrophotometry for drug
LogD determination in liposomes/aqueous systems. LogD
assessment by UV-Vis spectrophotometry was difficult
due to the strong light scattering spectral interference of
the lipid vesicles at low wavelength values. However, even
though similar results of LogD of Naproxen were obtained
in MLV either by UV-Vis derivative spectrophotometry
or by fluorescence spectroscopy, fluorescence emission
bands have lower light scattering effects, which are further
eliminated with the first derivative of the spectra. Fluorescence
spectroscopy also enabled the Naproxen LogD calculation
in LUVs, which was not possible by UV-Vis derivative
spectroscopy due to the strong spectral interference of the
lipid vesicles.
The high distribution of Naproxen in micelles, LUVs
and MLVs confirmed by the current experimental results
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FIGURE 10 | FLIM images showing cell uptake of DSPC:DODAP (2:1) nanocarriers loaded with Daunorubicin (0.5µM) using HeLa cells after (A) 15min of incubation
and (B) 4 h of incubation. In the image no membrane dye was employed and a false color range (0.5–2.0 ns) was used according to the fluorescence lifetimes
measured. Blue color corresponds to the longer lifetime (∼2 ns), while green color corresponds to intermediate lifetime (∼1.5 ns) and red color corresponds to shorter
lifetimes (∼0.5 ns). Fluorescence intensity histogram is represented along side the respective lifetime color bar.
FIGURE 11 | Schematic representation of the possible location/orientation of Tolmetin, Acemetacin, and Indomethacin molecules within the lipid nanocarrier
indicating the chemical groups likely responsible for fluorescence quenching of n-AS probes.
suggest an efficient encapsulation of this NSAID in lipid
nanocarriers, a strategy that could be of interest to improve
drug pharmacokinetics, namely its bioavailability after an oral
administration (Marjan et al., 2017).
Besides predicting drug distribution in lipid nanocarriers, it
is possible to foresee the drug location or molecule orientation
within the phospholipid components of a nanocarrier system.
A schematic representation of drugs possible location and
molecular orientation within the lipid nanocarrier (MLVs of
EPC) is presented in Figure 11.
In the present study, Acemetacin was able to quench the
fluorescence of all the probes probably due to an orientation
of the molecule anchored by its carboxyl group to the polar
nanocarrier headgroups and with its halogen, which constitutes
a strong deactivating group, situated at the deepest level of the
lipid nanocarrier near the 12-AS probe. Regarding the location
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of Indomethacin within the lipid nanocarrier, the sphere of
action model was used to define the quenching mechanism of
the n-As probes by the drug, resulting in a prediction of the
localization similar to that obtained for Acemetacin. Considering
the significantly lower K
app
q values determined for Tolmetin
(Table 2), it is expected that the penetration of this drug at
lipid bilayer level will be significantly reduced. The same type
of conclusions was obtained for the same NSAIDs when their
location was predicted in LUVs of EPC (Lucio et al., 2004) or in
LUVs of other lipid components (DMPC) with other membrane
probe (DPH) acting as molecular ruler (Lúcio et al., 2009). This
indicates that the drug location by fluorescence quenching is a
robust method to predict drug location and orientation within
a lipid nanocarrier. However, the K
app
q obtained in the previous
works (LUVs) were significantly smaller than the K
app
q obtained
in this work (MLVs), perhaps because by possessing a greater
number of lipid bilayers MLVs have a higher drug distribution
within those bilayers and thus the quenching efficiency is
enhanced.
Ultimately, predicting drug location and orientation within
a lipid nanocarrier is very important during the formulation
development, since it can provide information about the
nanocarrier optimization. For instance, if similar to Tolmetin, a
drug is located at the surface of the nanocarrier, its release maybe
very fast and the protection conferred by the nanocarrier might
be reduced during the drug delivery. In such cases the developing
team might consider changing the nanocarrier composition to
allow a deeper drug penetration, or even establish stronger
interactions between the drug and the nanocarrier surface by
grafting ligands to the drug that can avoid its rapid release.
After analyzing the drug distribution and the drug
location/orientation within the lipid nanocarrier it is also
essential to understand the impact of drug loading in the
biophysical properties of the nanocarrier (Peetla et al., 2009).
Indeed, a drug that is highly distributed within the nanocarrier,
may affect differently the nanocarrier microviscosity according
to the drug orientation and location. It has been described that
lipid assemblies have a microviscosity gradient, being more
ordered at the polar headgroup regions and less ordered at the
acyl fatty acid chains regions (Davis, 1983; Siminovitch et al.,
1983; Seelig and Seelig, 2009). Moreover, studying the impact
of drugs in the nanocarrier biophysical properties is paramount
as a great reduction of microviscosity can turn the nanocarrier
into a very leaky system that is not able to fulfill the role of drug
carrier with a controlled drug release (Peetla et al., 2009).
In the current study we have reached the conclusion that
all NSAIDs tested fluidized the membrane in a concentration-
dependent manner, after which an index was established to
compare the effectiveness of membrane fluidization (FE25). The
lower FE25 value, the lower concentration of drug required
to have a 25% fluidizing effect on the lipid nanocarrier and
therefore the efficacy of drug to induce membrane fluidity is
greater. Thus, by the analysis of the determined FE25, it is
possible to establish the following order of fluidization efficacy
of the lipid nanocarriers (MLVs of EPC) by the NSAIDs studied:
Indomethacin>Acemetacin>Tolmetin. A similar conclusion
was obtained for the same NSAIDs when their location was
predicted in LUVs of EPC (Lucio et al., 2004). The FE25 values
calculated herein are also useful for aiding in the optimization
of the nanocarrier loaded with the drug. In fact concentrations of
drug loaded in the lipid nanocarrier that induce a fluidizing effect
over 25% should be avoided at the risk of turning the nanocarrier
into a very permeable system. In this regard FE25 values are a
good indicator of the maximum amount of drug that should be
loaded in the nanocarrier system.
In addition to analyzing the differences observed between
the ability of the studied NSAIDs to fluidize the membrane as
a whole, it is also important to compare the results obtained
for each probe, since n-AS probes are located within the
lipid nanocarrier at different depths and can therefore provide
information about the fluidity gradient in these regions. All the
NSAIDs studied increase membrane fluidity for all probes and
the observed order is: 2-AS <6-AS <9-AS <12-AS. Our results
are in agreement with the literature, since according to lipid
membranes fluidity gradient, probes 2, 6 and 9-AS being located
nearer the polar headgroup region, a more ordered region, are
less susceptible to perturbations than the probe 12-AS located
closest to the center of the lipid bilayers of the lipid nanocarrier
system (Davis, 1983; Siminovitch et al., 1983; Seelig and Seelig,
2009). In addition, changes in membrane fluidity by NSAIDs
corroborate the findings of the location studies and there is a
parallelism between drug location within the lipid nanocarrier
and effects on membrane fluidity, since a membrane-disturbing
drug will have a greater propensity to disturb the surrounding
lipid microenvironment.
Besides being useful for the nanocarrier development and
optimization in the pre-formulation steps, in vitro studies are also
useful to provide a first approach of the NT performance. An
expected function of in vitro studies for therapeutic performance
evaluation is helping researchers to understand the factors that
dictate the outcome of NT/drug interactions with living systems,
in particular with serum proteins and biological barriers (such
as the membranes of the target cell tissues) without the need of
laborious and expensive in vivo studies. Animal models allow
the investigation of biological fate of NT/drugs but should be
reserved to final stages of their development. Indeed, animal
studies are labor-intensive, expensive and controversial. Due
to limitations of methodologies and to differences between
human/animal pathophysiology it is estimated that only 20%
of drug candidates tested successfully in animals passed clinical
trials (Perrin, 2014). Moreover, preserving animal health is in
agreement with the EU principles (Directive 2010/63/EU) of
Replacement (of animals for other relevant in vitro models),
Reduction (of animals tests) and Refinement (the “Three Rs”).
In this regard we propose two in vitro studies for a first
evaluation of the therapeutic performance of the NT. The first
study involves evaluation of the interaction between drug or
nanocarrier loaded with drug and the most abundant serum
carrier protein–HSA. The second study involves the evaluation
of NT or drug cellular uptake, by cells representative of the drug
target tissues.
By the results obtained in performance studies where the
binding strength to HSA of free Clonixin and DSPC:DODAP
(2:1) loaded with Clonixin was compared, it is possible to
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conclude that under both conditions there is a strong binding
to HSA at one binding site. As previously mentioned (Table 4),
there is a significant increase in the binding strength when
the drug is carried in the lipid nanosystem, stressing the need
to make improvements in the developed formulation. Indeed
positively charged nanocarriers have higher affinity to negatively
charged HSA residues. To reduce HSA binding and improve
drug circulation time, PEGylation of the nanosystems can be
a solution once polyethylene glycol (PEG) addition to the
nanocarrier surface is commonly used to: avoid recognition
by the RES cells, reduce the opsonization and plasma protein
binding and consequently prolong the systemic circulatory
life improving the desired physiological effect (Shi et al.,
2002).
Finally the cellular uptake of lipid nanocarriers loaded with
Daunorubicin was investigated in cancer cells using FLIM. This
in vitro assay is also extremely useful to evaluate the therapeutic
performance of a nanocarrier loadedwith drug, since it is possible
to follow drug distribution inside the cells (in the case of a
fluorescent drug) or even the nanocarrier distribution if a labeled
nanocarrier is applied. In our study, two incubation times of
cancer cells and NT loaded with anticancer drug Daunorubicin
were tested to evaluate the performance of the NT regarding
the capacity for an intracellular deliver of the drug. From the
images obtained it was possible to conclude that even at short
incubation times (15min) there was a distribution of the drug
in the cytoplasm, whereas for longer incubation periods (4 h)
the drug has visibly reached the cellular nucleus where it will
exert its effect. Therefore, the nanocarrier system appears to
be very effective delivering the drug in comparison to other
nanocarrier systems used for anthracycline drugs that reported
longer incubation periods for an effective drug distribution (Dai
et al., 2008; Basuki et al., 2013).
CONCLUSION
We present a toolbox of biophysical studies as strategies to
analyze:
- Drug distribution coefficient (LogD) between the lipid
phases of the nanocarrier and the aqueous phase by
derivative spectroscopy, leading to the determination of
drug encapsulation. As an a lipophilic drug, Naproxen, was
analyzed, and the LogD values >3.0 confirmed the lipophilic
nature of the drug and the adequacy of lipid nanocarriers for
its encapsulation
- Drug location in lipid nanocarriers by fluorescence quenching
where the decrease on fluorescence intensity of extrinsic
probes was measured to indicate the drug distribution and
possible orientation within the nanocarrier. Acemetacin and
Indomethacin can reach an inner location at the lipid
nanocarrier while being anchored with its carboxylic moiety
at the polar headgroup. The least observed quenching effect
suggested that Tolmetin is probably located at the polar
headgroup region of the lipid nanocarriers and this superficial
location may translate in a fast drug release from the
nanocarriers.
- Drug effect on NT biophysical properties using fluorescence
anisotropy. This study is important because a great increase
of the fluidity of the nanocarrier lipid system can turn it
into a too leaky and not so stable carrier for the drug.
Fluorescent anisotropymeasurements indicated that the drugs
deeply buried within the lipid nanocarrier (Acemetacin
and Indomethacin) where the ones that had a greater
fluidizing effect which can also translate in a faster drug
release.
- NT interaction with plasma proteins by measuring
fluorescence quenching of intrinsic probes (protein
fluorescent residues), as this is paramount to assure that
the NT will reach the target tissues and will not have an
exceeding circulation time. Clonixin after encapsulation in
a lipid nanocarrier DSPC:DODAP (2:1) has still a strong
binding to serum albumin, at one binding site, suggesting the
need to produce a stealth nanosystem.
- Cellular uptake of NT analyzed by FLIM. As an example we
have followed the uptake of lipid nanocarriers loaded with
Daunorubicin by cancer cells. From the images obtained it was
possible to conclude that at short incubation times (15min)
there was a distribution of the drug in the cytoplasm, whereas
for longer incubation periods (4 h) the drug has reached the
nucleus.
Results obtained provide an insight at the use of spectroscopic
techniques as a toolkit for in vitro screening of drug-
membrane biophysical interactions to predict at an early stage of
development in vivo aspects related with lipid nanotherapeutics
performance.
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EU: an overview on current state and future directions. Int. J. Nanomed. 9,
1005–1023. doi: 10.2147/ijn.S55359
Kerns, E. H., and Di, L. (2008). “Chapter 14-plasma protein binding,” in Drug-Like
Properties: Concepts, Structure Design and Methods (San Diego, CA: Academic
Press), 187–196. Available online at: https://www.sciencedirect.com/science/
book/9780123695208
Kitamura, K., and Imayoshi, N. (1992). Second-derivative spectrophotometric
determination of the binding constant between chlorpromazine
and beta-cyclodextrin in aqueous solutions. Anal. Sci. 8, 497–501.
doi: 10.2116/analsci.8.497
Kitamura, K., Imayoshi, N., Goto, T., Shiro, H., Mano, T., and Nakai, Y.
(1995). Second derivative spectrophotometric determination of partition
coefficients of chlorpromazine and promazine between lecithin bilayer vesicles
and water. Anal. Chim. Acta 304, 101–106. doi: 10.1016/0003-2670(94)
00566-5
Lakowicz, J. R. (2014). Principles of Fluorescence Spectroscopy. New York, NY:
Springer.
Lasic, D. D. (1993). Liposomes: From Physics to Applications. New York, NY:
Elsevier.
Liu, B., Yang, C., Yan, X., Wang, J., and Lv, Y. (2012). Interaction of avelox with
bovine serum albumin and effect of the coexistent drugs on the reaction. Int. J.
Anal. Chem. 2012, 1–8. doi: 10.1155/2012/408057
Lúcio, M., Ferreira, H., Jose, L. F. C. L., and Salette, R. (2006). Interactions
between oxicams and membrane bilayers: an explanation for their different
COX selectivity. Med. Chem. 2, 447–456. doi: 10.2174/157340606778
250199
Lucio, M., Ferreira, H., Lima, J. L. F. C., Matos, C., de Castro, B., and Reis, S. (2004).
Influence of some anti-inflammatory drugs in membrane fluidity studied by
fluorescence anisotropy measurements. Phys. Chem. Chem. Phys. 6, 1493–1498.
doi: 10.1039/B314551B
Lúcio, M., Nunes, C., Gaspar, D., Gołebska, K., Wisniewski, M., Lima, J. L. F.
C., et al. (2009). Effect of anti-inflammatory drugs in phosphatidylcholine
membranes: a fluorescence and calorimetric study. Chem. Phys. Lett. 471,
300–309. doi: 10.1016/j.cplett.2009.02.047
Ma, J. K. H., and Hadzija, B. (2013). Basic Physical Pharmacy. Burlington, MA:
Jones & Bartlett Learning.
Magalhães, L. M., Nunes, C., Lúcio, M., Segundo, M. A., Reis, S., and Lima, J. L.
F. C. (2010). High-throughput microplate assay for the determination of drug
partition coefficients. Nat. Protoc. 5, 1823–1830. doi: 10.1038/nprot.2010.137
Marjan, D., Simin, D., Azadeh, H., and Masoud Faghih, A. (2017). Potential of
liposomes for enhancement of oral drug absorption. Curr. Drug Deliv. 14,
289–303. doi: 10.2174/1567201813666160115125756
Maynard, A. D., Aitken, R. J., Butz, T., Colvin, V., Donaldson, K., Oberdörster,
G., et al. (2006). Safe handling of nanotechnology. Nature 444, 267–269.
doi: 10.1038/444267a
Monteiro, J. P., Martins, A. F., Lúcio, M., Reis, S., Pinheiro, T. J. T., Geraldes, C.
F. G. C., et al. (2011). Nimesulide interaction with membrane model systems:
Frontiers in Chemistry | www.frontiersin.org 19 July 2018 | Volume 6 | Article 323
Fernandes et al. Spectroscopic Characterization of Lipid Nanotherapeutics
are membrane physical effects involved in nimesulide mitochondrial toxicity?
Toxicol. In Vitro 25, 1215–1223. doi: 10.1016/j.tiv.2011.05.014
New, R. R. C. (1990). Liposomes: A Practical Approach. New York, NY: Oxford
University Press.
Omran, A. A., Kitamura, K., Takegami, S., El-Sayed, A. A. Y., and Abdel-
Mottaleb, M. (2001). Determination of partition coefficients of diazepam and
flurazepam between phosphatidylcholine bilayer vesicles and water by second
derivative spectrophotometric method. J. Pharm. Biomed. Anal. 25, 319–324.
doi: 10.1016/S0731-7085(00)00503-3
Peetla, C., Stine, A., and Labhasetwar, V. (2009). Biophysical interactions
with model lipid membranes: applications in drug discovery and
drug delivery. Mol. Pharm. 6, 1264–1276. doi: 10.1021/mp90
00662
Pereira-Leite, C., Carneiro, C., Soares, J. X., Afonso, C., Nunes, C., Lúcio, M.,
et al. (2013). Biophysical characterization of the drug–membrane interactions:
the case of propranolol and acebutolol. Eur. J. Pharm. Biopharm. 84, 183–191.
doi: 10.1016/j.ejpb.2012.12.005
Perrin, S. (2014). Preclinical research: make mouse studies work. Nature 507,
423–425. doi: 10.1038/507423a
Pinheiro, M., Lúcio, M., Lima, J. L., and Reis, S. (2011). Liposomes as drug
delivery systems for the treatment of TB. Nanomedicine 6, 1413–1428.
doi: 10.2217/nnm.11.122
Qi, J., Zhuang, J., Lu, Y., Dong, X., Zhao, W., and Wu, W. (2017). In
vivo fate of lipid-based nanoparticles. Drug Discov. Today 22, 166–172.
doi: 10.1016/j.drudis.2016.09.024
Saakov, V. S., Krivchenko, A. I., Rozengart, E. V., and Danilova, I. G.
(2015). Derivative Spectrophotometry and Pam-Fluorescence in Comparative
Biochemistry. Basel: Springer International Publishing AG.
Santos, N. C., and Castanho, M. A. (1996). Teaching light scattering spectroscopy:
the dimension and shape of tobacco mosaic virus. Biophys. J. 71, 1641–1650.
doi: 10.1016/S0006-3495(96)79369-4
Santos, N. C., Prieto, M., and Castanho, M. A. R. B. (1998). Interaction
of the major epitope region of HIV Protein gp41 with membrane model
systems. A Fluoresc. Spectrosc. Study Biochem. 37, 8674–8682. doi: 10.1021/bi98
03933
Seelig, J., and Seelig, A. (2009). Lipid conformation in model
membranes and biological membranes. Q. Rev. Biophys. 13, 19–61.
doi: 10.1017/S0033583500000305
Shi, F., Wasungu, L., Nomden, A., Stuart, M. C. A., Polushkin, E., Engberts, J.
B. F. N., et al. (2002). Interference of poly(ethylene glycol)-lipid analogues
with cationic-lipid-mediated delivery of oligonucleotides; role of lipid
exchangeability and non-lamellar transitions. Biochem. J. 366(Pt 1), 333–341.
doi: 10.1042/BJ20020590
Sikaris, K. A., and Sawyer, W. H. (1982). The interaction of local anaesthetics
with synthetic phospholipid bilayers. Biochem. Pharmacol. 31, 2625–2631.
doi: 10.1016/0006-2952(82)90709-2
Siminovitch, D. J., Jeffrey, K. R., and Eibl, H. (1983). A comparison
of the headgroup conformation and dynamics in synthetic analogs of
dipalmitoylphosphatidylcholine. Biochim. Biophys. Acta. Biomembr. 727,
122–134. doi: 10.1016/0005-2736(83)90376-0
Than Htun, M. (2009). Photophysical study on daunorubicin by fluorescence
spectroscopy. J. Lumin. 129, 344–348. doi: 10.1016/j.jlumin.2008.10.020
Trynda-Lemiesz, L. (2004). Paclitaxel–HSA interaction. binding
sites on HSA molecule. Bioorganic Med. Chem. 12, 3269–3275.
doi: 10.1016/j.bmc.2004.03.073
Vincent, M., De Foresta, B., Gallay, J., and Alfsen, A. (1982). Nanosecond
fluorescence anisotropy decays of n-(9-anthroyloxy) fatty acids in
dipalmitoylphosphatidylcholine vesicles with regard to isotropic solvents.
Biochemistry 21, 708–716. doi: 10.1021/bi00533a019
Wacker, M. G. (2014). Nanotherapeutics-product development along the
“nanomaterial” discussion. J. Pharm. Sci. 103, 777–784. doi: 10.1002/jps.23879
Weissig, V., Pettinger, T. K., and Murdock, N. (2014). Nanopharmaceuticals
(part 1): products on the market. Int. J. Nanomed. 9, 4357–4373.
doi: 10.2147/IJN.S46900
Yang, F., Zhang, Y., and Liang, H. (2014). Interactive association of drugs
binding to human serum albumin. Int. J. Mol. Sci. 15, 3580–3595.
doi: 10.3390/ijms15033580
Yoo, Y., Shin, H.-W., and Nam, B.-G. (2003). Effect of hydrophilic-lipophilic
balance of drugs on their release behavior from amphiphilic matrix.Macromol.
Res. 11, 283–290. doi: 10.1007/bf03218365
Zhu, H., Sarkar, S., Scott, L., Danelisen, I., Trush, M. A., Jia, Z., et al.
(2016). Doxorubicin redox biology: redox cycling, topoisomerase
inhibition, and oxidative Stress. Reactive Oxygen Species. 1, 189–198.
doi: 10.20455/ros.2016.835
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2018 Fernandes, Soares, Gonçalves and Lúcio. This is an open-access
article distributed under the terms of the Creative Commons Attribution License (CC
BY). The use, distribution or reproduction in other forums is permitted, provided
the original author(s) and the copyright owner(s) are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Chemistry | www.frontiersin.org 20 July 2018 | Volume 6 | Article 323
